Baron Opportunity Fund (BIOPX)

Portfolio Management

Michael Lippert

Fund Manager since 2006

View All Commentary by Michael

Fund Description

Baron Opportunity Fund invests in innovative high-growth companies.



Portfolio Commentary

Retail Performance

Review and Outlook (for quarter ended 9/30/2016)

The Review and Outlook for period ending September 30, 2016 is not yet available

Top Contributors/Detractors to Performance

Contributors (for quarter ended 9/30/2016)
  • Shares of, Inc., the world’s largest retailer and cloud services provider, rose in Q3 after reporting strong revenue growth and improving margins in its core business. Amazon’s other major business segment, Amazon Web Services (AWS), continues to gain traction with enterprise customers, and had another strong quarter of growth. Over time, we expect AWS to be the larger contributor to value creation. The company continues to invest in new and potentially large business segments such as e-finance, business supplies and apparel.

  • Alphabet Inc. is the world’s largest search and online advertising company. Shares of Alphabet were up in Q3, driven by quarterly results that surpassed Wall Street expectations. We continue to believe that even while desktop search is becoming a more mature business for the company, Alphabet is well positioned to benefit from substantial growth in mobile and online video advertising.

  • Acxiom Corporation is a leader in marketing data services and identity management for enterprises. Shares of Acxiom were up in Q3, driven by rapid growth in the company’s cloud-based connectivity and identity business. We believe that Acxiom is benefiting from a streamlining of operations and a focus on returning the core business to profitable growth while accelerating the growth of its new LiveRamp business.

Detractors (for quarter ended 9/30/2016)
  • Bristol-Myers Squibb Company is a large diversified pharmaceutical leading the development of immune stimulating therapies for oncology. These efforts are spearheaded by its product Opdivo, now approved to treat several types of cancer. After positive data was released on a rival drug to treat first-line advanced non-small-cell lung cancer, Bristol-Myers revealed that Opdivo did not meet the primary endpoint in a Phase III trial in the same indication, and shares fell. We are analyzing the competitor’s trial results and Bristol-Myers data sets.

  • Shares of Gartner, Inc., a provider of syndicated IT research, relinquished some gains due to tougher comparisons and slightly more challenging macro conditions. We believe Gartner’s key metrics are solid. The company has significant financial flexibility, and we think it will aggressively deploy capital for repurchases or mergers and acquisitions. Over time, in our view, Gartner will generate accelerating top line growth, significant growth in earnings and free cash flow, and persistent return of capital.

  • Shares of cloud computing pioneer, inc. decreased in Q3. The company reported mixed bookings results due to execution issues in the domestic market. We believe that salesforce’s addressable market is more than 10 times larger than its current run rate revenue, giving it ample opportunity to compound revenue in excess of 20% annually. We believe the company is highly innovative, and has a strong track record of disrupting legacy environments with next-generation software.

Quarterly Attribution Analysis (for quarter ended 9/30/2016)

The Quarterly Attribution Analysis for period ending September 30, 2016 is not yet available

Back to Top

Invest In Baron Funds Today

The prospective performance of the companies discussed herein is based on our internal analysis and reflect our opinions only. We cannot promise future returns and our opinions are a reflection of our best judgement at the time of publication. Our views are not intended as recommendations or investment advice to any person and are subject to change at any time based on market and other conditions and Baron has no obligation to update them. Investing in the stock market is always risky. Current and future portfolio holdings in the Fund are subject to risk.

Source: FactSet PA